Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 1/20 | 0.32 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.32 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.32 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL578419 | 0.83 | JAK2 (0.31) | SMN1; SMN2 | |
| SCHEMBL6979479 | 0.83 | CYP2C19 (0.33) | GNAI3GNAO1GNAI1SMYD3 | |
| SCHEMBL17110192 | 0.83 | GNAI3 (0.32) | GNAI3GNAO1GNAI1SMYD3 | |
| SCHEMBL1768062 | 0.82 | — | — | |
| Hydrochloric Acid SCHEMBL385319 | 0.82 | GNAI3 (0.34) | GNAI3GNAO1GNAI1SMYD3 | |
| Hydrochloric Acid SCHEMBL385321 | 0.82 | GNAI3 (0.34) | GNAI3GNAO1GNAI1SMYD3 | |
| Hydrochloric Acid SCHEMBL27793068 | 0.80 | — | — | |
| SCHEMBL9603340 | 0.80 | GNAI3 (0.41) | GNAI3GNAO1GNAI1 | |
| SCHEMBL1810305 | 0.78 | CYP2C19 (0.38) | SMN1; SMN2 | |
| SCHEMBL1768081 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040063701-A1 | Piperidine derivatives and anti-platelet agents containing the same | AJINOMOTO CO., INC (JP) | 2004-04-01 | — | — | US | claimed |
| US-20020147195-A1 | Piperidine derivatives and anti-platelet agents containing the same | AJINOMOTO CO., INC. (JP) | 2002-10-10 | — | — | US | claimed |
| US-20020019533-A1 | PIPERIDINE DERIVATIVES AND ANTI-PLATELET AGENTS CONTAINING THE SAME | MAKINO SHINGO (JP) | 2002-02-14 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019533-A1 | PIPERIDINE DERIVATIVES AND ANTI-PLATELET AGENTS CONTAINING THE SAME | HTR2A, PDGFRA, PDGFRB | GNAI3 1321/4885GNAO1 2039/4885GNAI1 1353/4885 |
| US-20020147195-A1 | Piperidine derivatives and anti-platelet agents containing the same | HTR2A, PDGFRA, PDGFRB | GNAI3 1321/4885GNAO1 2039/4885GNAI1 1353/4885 |
| US-20040063701-A1 | Piperidine derivatives and anti-platelet agents containing the same | HTR2A, PDGFRA, PDGFRB | GNAI3 1321/4885GNAO1 2039/4885GNAI1 1353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.